Cargando…

Cryopreservation-related loss of antigen-specific IFNγ producing CD4(+) T-cells can skew immunogenicity data in vaccine trials: Lessons from a malaria vaccine trial substudy

Ex vivo functional immunoassays such as ELISpot and intracellular cytokine staining (ICS) by flow cytometry are crucial tools in vaccine development both in the identification of novel immunogenic targets and in the immunological assessment of samples from clinical trials. Cryopreservation and subse...

Descripción completa

Detalles Bibliográficos
Autores principales:	Ford, Tom, Wenden, Claire, Mbekeani, Alison, Dally, Len, Cox, Josephine H., Morin, Merribeth, Winstone, Nicola, Hill, Adrian V.S., Gilmour, Jill, Ewer, Katie J.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Elsevier Science 2017
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5387668/ https://www.ncbi.nlm.nih.gov/pubmed/28285985 http://dx.doi.org/10.1016/j.vaccine.2017.02.038

Ejemplares similares

The Impact of Improved Water, Sanitation, and Hygiene on Oral Rotavirus Vaccine Immunogenicity in Zimbabwean Infants: Substudy of a Cluster-randomized Trial
por: Church, James A, et al.
Publicado: (2019)

Safety and Immunogenicity of DNA and MVA HIV-1 Subtype C Vaccine Prime-Boost Regimens: A Phase I Randomised Trial in HIV-Uninfected Indian Volunteers
por: Mehendale, Sanjay, et al.
Publicado: (2013)

A first-in-human trial on the safety and immunogenicity of COVID-eVax, a cellular response-skewed DNA vaccine against COVID-19
por: Aurisicchio, Luigi, et al.
Publicado: (2023)

Performance of International AIDS Vaccine Initiative African clinical research laboratories in standardised ELISpot and peripheral blood mononuclear cell processing in support of HIV vaccine clinical trials
por: Langat, Robert K., et al.
Publicado: (2021)

In Vivo Electroporation Enhances the Immunogenicity of an HIV-1 DNA Vaccine Candidate in Healthy Volunteers
por: Vasan, Sandhya, et al.
Publicado: (2011)

Safety and immunogenicity of a parenteral trivalent P2-VP8 subunit rotavirus vaccine: a multisite, randomised, double-blind, placebo-controlled trial
por: Groome, Michelle J, et al.
Publicado: (2020)

Safety, immunogenicity, and efficacy of a COVID-19 vaccine (NVX-CoV2373) co-administered with seasonal influenza vaccines: an exploratory substudy of a randomised, observer-blinded, placebo-controlled, phase 3 trial
por: Toback, Seth, et al.
Publicado: (2022)

Safety and immunogenicity of a typhoid conjugate vaccine among children aged 9 months to 12 years in Malawi: a nested substudy of a double-blind, randomised controlled trial
por: Nampota-Nkomba, Nginache, et al.
Publicado: (2022)

Safety and immunogenicity of a parenteral P2-VP8-P[8] subunit rotavirus vaccine in toddlers and infants in South Africa: a randomised, double-blind, placebo-controlled trial
por: Groome, Michelle J, et al.
Publicado: (2017)

Activation-induced Markers Detect Vaccine-Specific CD4(+) T Cell Responses Not Measured by Assays Conventionally Used in Clinical Trials
por: Bowyer, Georgina, et al.
Publicado: (2018)

Cellular and molecular synergy in AS01-adjuvanted vaccines results in an early IFNγ response promoting vaccine immunogenicity
por: Coccia, Margherita, et al.
Publicado: (2017)

Covid-19 vaccine trials: Ethnic diversity and immunogenicity
por: Jethwa, Hannah, et al.
Publicado: (2021)

Safety and Immunogenicity Study of Multiclade HIV-1 Adenoviral Vector Vaccine Alone or as Boost following a Multiclade HIV-1 DNA Vaccine in Africa
por: Jaoko, Walter, et al.
Publicado: (2010)

Tolerability and immunogenicity of an intranasally-administered adenovirus-vectored COVID-19 vaccine: An open-label partially-randomised ascending dose phase I trial
por: Madhavan, Meera, et al.
Publicado: (2022)

Phase 1 Safety and Immunogenicity Evaluation of ADVAX, a Multigenic, DNA-Based Clade C/B' HIV-1 Candidate Vaccine
por: Vasan, Sandhya, et al.
Publicado: (2010)

A review of Phase I trials of Ebola virus vaccines: what can we learn from the race to develop novel vaccines?
por: Lambe, Teresa, et al.
Publicado: (2017)

Author Correction: Cellular and molecular synergy in AS01-adjuvanted vaccines results in an early IFNγ response promoting vaccine immunogenicity
por: Coccia, Margherita, et al.
Publicado: (2018)

Safety and Immunogenicity of Malaria Vectored Vaccines Given with Routine Expanded Program on Immunization Vaccines in Gambian Infants and Neonates: A Randomized Controlled Trial
por: Mensah, Victorine A., et al.
Publicado: (2017)

Baseline Morbidity in 2,990 Adult African Volunteers Recruited to Characterize Laboratory Reference Intervals for Future HIV Vaccine Clinical Trials
por: Stevens, Wendy, et al.
Publicado: (2008)

Safety and immunogenicity of the ChAdOx1 nCoV-19 (AZD1222) vaccine against SARS-CoV-2 in HIV infection: a single-arm substudy of a phase 2/3 clinical trial
por: Frater, John, et al.
Publicado: (2021)

Humoral immunogenicity of ChAd63_MVA ME-TRAP vaccination in African infants and children
por: Bowyer, Georgina, et al.
Publicado: (2014)

Impact of Withholding Breastfeeding at the Time of Vaccination on the Immunogenicity of Oral Rotavirus Vaccine—A Randomized Trial
por: Ali, Asad, et al.
Publicado: (2015)

Immunogenicity and safety of fractional doses of 17D-213 yellow fever vaccine in HIV-infected people in Kenya (YEFE): a randomised, double-blind, non-inferiority substudy of a phase 4 trial
por: Kimathi, Derick, et al.
Publicado: (2023)

Phase 1 Safety and Immunogenicity Evaluation of ADMVA, a Multigenic, Modified Vaccinia Ankara-HIV-1 B'/C Candidate Vaccine
por: Vasan, Sandhya, et al.
Publicado: (2010)

CMV-associated T cell and NK cell terminal differentiation does not affect immunogenicity of ChAdOx1 vaccination
por: Sharpe, Hannah R., et al.
Publicado: (2022)

Skewed risk perceptions in pregnant women: the case of influenza vaccination
por: Bödeker, Birte, et al.
Publicado: (2015)

A Phase I Double Blind, Placebo-Controlled, Randomized Study of the Safety and Immunogenicity of Electroporated HIV DNA with or without Interleukin 12 in Prime-Boost Combinations with an Ad35 HIV Vaccine in Healthy HIV-Seronegative African Adults
por: Mpendo, Juliet, et al.
Publicado: (2015)

OA07-04 LB. Immunogenicity of ALVAC-HIV® (vCP1521) and AIDSVAX® B/E prime boose vaccination in RV144, the Thai Phase III HIV vaccine trial
por: de Souza, MS, et al.
Publicado: (2009)

Correction: Impact of Withholding Breastfeeding at the Time of Vaccination on the Immunogenicity of Oral Rotavirus Vaccine—A Randomized Trial
por: Ali, Asad, et al.
Publicado: (2015)

Safety and Immunogenicity of a Novel Recombinant Simian Adenovirus ChAdOx2 as a Vectored Vaccine
por: Folegatti, Pedro M., et al.
Publicado: (2019)

Effect of Anacetrapib on Cholesterol Efflux Capacity: A Substudy of the DEFINE Trial
por: Metzinger, Mark P., et al.
Publicado: (2020)

Evaluation of pneumococcal and tetanus vaccine responses in patients with rheumatoid arthritis receiving baricitinib: results from a long-term extension trial substudy
por: Winthrop, Kevin L., et al.
Publicado: (2019)

Immunogenicity and Viral Shedding of Russian-Backbone, Seasonal, Trivalent, Live, Attenuated Influenza Vaccine in a Phase II, Randomized, Placebo-Controlled Trial Among Preschool-Aged Children in Urban Bangladesh
por: Lewis, Kristen D C, et al.
Publicado: (2019)

Safety and immunogenicity of a plant-produced Pfs25 virus-like particle as a transmission blocking vaccine against malaria: A Phase 1 dose-escalation study in healthy adults
por: Chichester, Jessica A., et al.
Publicado: (2018)

Immunogenicity Measures of Influenza Vaccines: A Study of 1164 Registered Clinical Trials
por: Domnich, Alexander, et al.
Publicado: (2020)

Analyzing the immunogenicity of bivalent booster vaccinations in healthcare workers: The SWITCH ON trial protocol
por: Tan, Ngoc H., et al.
Publicado: (2022)

Safety and immunogenicity of Zika virus vaccine: A systematic review of clinical trials
por: Yeasmin, Mahmuda, et al.
Publicado: (2022)

Effect of vaccine dose on the safety and immunogenicity of a candidate TB vaccine, MVA85A, in BCG vaccinated UK adults
por: Pathan, Ansar A., et al.
Publicado: (2012)

First-in-Human Evaluation of the Safety and Immunogenicity of an Intranasally Administered Replication-Competent Sendai Virus–Vectored HIV Type 1 Gag Vaccine: Induction of Potent T-Cell or Antibody Responses in Prime-Boost Regimens
por: Nyombayire, Julien, et al.
Publicado: (2017)

MIG (CXCL9) is a more sensitive measure than IFN-γ of vaccine induced T-cell responses in volunteers receiving investigated malaria vaccines
por: Berthoud, Tamara K., et al.
Publicado: (2009)

Cannot write session to /tmp/vufind_sessions/sess_faabmohk48ud7le6fht5oj8gka